Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Research Study Number 20160524
 
Principal Investigator Gabriela Chiorean
 
Phase I

Research Study Description

Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20160524
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Bladder Cancer; Breast Cancer; Esophageal Cancer; Gastrointestinal Cancer; Gynecological Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lung Cancer; Melanoma; Mesothelioma; Pancreatic Cancer; Prostate Cancer; Salivary Gland Cancer; Sarcoma; Solid Tumors; Thyroid Cancer; Colorectal Neoplasms; Esophageal Diseases; Gastrointestinal Diseases; Liver Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials